Overview A Dose-Escalation Study in Participants With Advanced Cancer Status: Completed Trial end date: 2016-01-01 Target enrollment: Participant gender: Summary This study is a multicenter, open-label, dose-escalation phase 1 study of intravenous (IV) LY2495655 in participants with advanced cancer. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company